Key clinical point:
Major finding: The overall response rate was 100%.
Study details: Phase 1b/2 trial in patients with multiple myeloma relapsed or refractory to at least 3 prior lines of therapy.
Disclosures: The CARTITUDE-1 trial is funded by Janssen Research & Development. Dr. Madduri disclosed serving as a consultant to Janssen and to Takeda, Foundation Medicine, AbbVie, and Celgene.
Madduri D et al. ASH 2019..